Bristol Myers Squibb International Corporation — Sponsor Intelligence | 29 EU Trials

Filter these 29 trials by condition, phase, country and more.

Open in Search →

29 Registered trials

0 Recruiting

31 Completed trials

17 Countries active

36 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 8 Phase II: 8 Phase I/II: 9 Phase I: 1 Phase I (FiH): 2 Other: 1

Oversight events:

6 temporary halts across 3 trials

View oversight register →

100%

31 of 31 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hepatocellular carcinoma 4 Non-small cell lung cancer 4 Bladder cancer 2 Ovarian cancer 2 Renal cell carcinoma 2 Small cell lung cancer extensive stage 2 Colorectal cancer 2 Gastric cancer 2 Oesophageal adenocarcinoma stage III 1 Peritoneal carcinoma metastatic 1 Renal cell carcinoma stage IV 1 Fallopian tube cancer 1

Top IMPs

NIVOLUMAB 20 IPILIMUMAB 10 RELATLIMAB 6 CISPLATIN 3 NIVOLUMAB, RELATLIMAB 3 PACLITAXEL 3 PEMETREXED 3 CARBOPLATIN 2 FARLETUZUMAB ECTERIBULIN 2 HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST FUCOSYL-GM1 2 REGORAFENIB 2 [89ZR]BMS-986279 1

All trials

29 total

Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch… Ended

2022-502354-14-00 Phase III 15 countries NIVOLUMAB
A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors Ended

2022-500823-61-00 Phase I (FiH) 2 countries BMS-986408; IPILIMUMAB; NIVOLUMAB
Phase 1 Study of BMS-986416 with and without Nivolumab in Solid Tumors Ended

2022-501317-31-00 2 countries
A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended

2023-504111-33-00 Phase II 3 countries DOXORUBICIN HYDROCHLORIDE; FARLETUZUMAB ECTERIBULIN
Phase 2 Study of MORAb-202 in Previously Treated Metastatic NSCLC AC Ended

2023-504112-15-00 Phase II 2 countries FARLETUZUMAB ECTERIBULIN
Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended

2023-503715-14-00 Phase I/II 4 countries NIVOLUMAB; RELATLIMAB
A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors Ended

2023-508280-69-00 Phase I 2 countries
Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended

2024-510649-33-00 Phase I/II 5 countries BEVACIZUMAB; NIVOLUMAB; RELATLIMAB
A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect… Ended

2023-503797-21-00 Phase III 10 countries NIVOLUMAB, RELATLIMAB; REGORAFENIB; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Ended

2023-508954-25-00 Phase I (FiH) 3 countries BMS-986288; NIVOLUMAB; REGORAFENIB
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III… Ended

2023-507688-20-00 Phase III 13 countries NIVOLUMAB; NIVOLUMAB, RELATLIMAB
A Study of BMS-986012 in Combination with Carboplatin, Etoposide, andNivolumab as First-line Therapy in Extensive-stage Small Cell Lung Canc… Ended

2024-510700-36-00 Phase II 7 countries [89ZR]BMS-986279; HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST FUCOSYL-GM1; NIVOLUMAB
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab Ended

2024-515490-10-00 Phase II 1 country ELOTUZUMAB
A Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Liver Cancer who have never been been Treated with Immuno-… Ended

2023-503519-13-00 Phase II 5 countries NIVOLUMAB; RELATLIMAB
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Phase III 11 countries CARBOPLATIN; CISPLATIN; DURVALUMAB; ETOPOSIDE; IPILIMUMAB; NIVOLUMAB; PACLITAXEL…
Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus Ended

2022-502444-13-00 Phase II 4 countries DEUCRAVACITINIB
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread Ended

2023-508207-21-00 Phase I/II 3 countries IPILIMUMAB; LINRODOSTAT MESILATE; NIVOLUMAB; RELATLIMAB
Study of subcutaneous nivolumab monotherapy with or without Recombinant Human Hyaluronidase PH20 (rHuPH20) Ended

2023-503554-12-00 Phase I/II 5 countries NIVOLUMAB
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum… Ended

2023-509061-20-00 Phase I/II 6 countries ANTI-IL-8 HUMAN MONOCLONAL ANTIBODY; IPILIMUMAB; NIVOLUMAB
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended

2023-508757-75-00 Phase III 7 countries CISPLATIN; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMETREXED
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer Ended

2022-502909-15-00 Phase II 1 country CABAZITAXEL; IPILIMUMAB; NIVOLUMAB
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung… Ended

2022-501360-18-00 Phase III 4 countries CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IPILIMUMAB; NIVOLUMAB; PACLITAXE…
A trial of BMS-986012 in combination with chemotherapy for small cell lung cancer Ended

2024-511824-15-00 Phase I/II 1 country HUMAN IGG1 MONOCLONAL ANTIBODY AGAINST FUCOSYL-GM1
A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended

2023-509360-24-00 Phase III 10 countries NIVOLUMAB

Showing 1–24 of 29 trials

← All sponsors A–Z